Shares of Takeda Pharmaceutical Co Ltd (TAK) plummeted 5.01% in pre-market trading on Thursday following the release of its fiscal fourth-quarter earnings report, which showed a significant decline in core earnings.
The Japanese pharmaceutical giant reported quarterly earnings of $0.16 per share, marking a substantial 33.33% decrease from $0.24 per share in the same period last year. Sales also saw a slight dip, coming in at $7.02 billion for the quarter, down 0.93% from $7.08 billion in the previous year.
The disappointing earnings report comes amid a broader downturn in the healthcare sector. The Health Care Select Sector SPDR Fund (XLV) was down 0.9% pre-market, while the iShares Biotechnology ETF (IBB) declined 0.7%. Takeda's performance, however, stood out with its more pronounced drop, reflecting investors' concerns about the company's financial health and growth prospects in a challenging market environment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。